Symptomatic antidiabetic protein kinase C inhibitor

Drugs of the Future

Volumn 25, Issue 10, 2000, Pages 1017-1026

  Sorbera, L A ^a   Silvestre, J ^a   Rabasseda, X ^a   Castaner, J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; ISOENZYME; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; PLACEBO; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; STAUROSPORINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HEADACHE; HUMAN; HYPERGLYCEMIA; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RAT; RETINA MACULA EDEMA; REVIEW;

EID: 0033635922     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.10.594264     Document Type: Review

References (63)

1. Macrocyclic bisindolylmaleimides: Synthesis by inter- and intramolecular alkylation
2. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase Cβ
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
4. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
5. Diseases of the retina
6. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
7. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
8. TPA-induced contraction of isolated rabbit vascular smooth muscle
9. Tumor-promoting phorbol esters induce angiogenesis in vitro
10. Migration of retinal pigment epithelium cells in vitro is regulated by protein kinase C
11. 2+-dependent translocation domain with homology to PKC and GAP
12. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: Possible mediation via protein kinase C
13. 2
14. Structural basis for species-specific differences in the phosphorylation of Na,K-ATPase by protein kinase C
15. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy
16. Protein kinase C activation and the development of diabetic complications
17. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions
18. Protein kinases C: Potential targets for intervention in diabetic nephropathy
19. Evidence for existence of polyol pathway in cultured rat mesangial cells
20. Sorbitol, phosphoinositides, and sodium potassium-ATPase in the pathogenesis of diabetic complications
21. Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells
22. Hyperglycemic pseudohypoxia and diabetic complications
23. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions
24. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
25. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose
26. Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells
27. Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor
28. 2+ dependent protein kinase
29. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251
30. Synthesis and SAR of protein kinase C (PKC) selective inhibitors: 14 Membered bisindolylmaleimide macrocycles
31. Macrocycle (bis)indolylmaleimides: Isozyme selective inhibitors of protein kinase C (PKC)
32. Synthesis of LY333531, an isozyme selective inhibitor of protein kinase Cβ (PKCβ): Part I - Chemistry of bisindolylmaleimides
33. Synthesis of LY333531, an isozyme selective inhibitor of protein kinase Cβ (PKCβ): Part II - Approaches to the synthesis of the 6 atom bridge
34. Efficient total synthesis of the PKC-β inhibitor LY333531. New methodology for the synthesis of bisindolylmaleimides
35. Identification of the cytochrome P450 responsible for the formation of the N-desmethyl (NDM) metabolite of LY333531
36. Effect of protein kinase Cβ selective inhibitors on insulin secretion and beta cell activity
37. Inhibition of protein kinase C (PKC) normalized endothelial nitric oxide synthase (eNOS) expression in vascular tissues of obese Zucker rats
38. βII protein kinase inhibition prevents and reverses in vivo endothelial nitric oxide suppression during acute hyperglycemia
39. Characterization of protein kinase Cβ isoform activation on the gene expression of transforming growth factor β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats
40. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCβ inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes
41. PKC-β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats
42. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases
43. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531
44. A protein kinase Cβ-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats
45. Interactions between protein kinase Cβ inhibition antioxidants and essential fatty acid treatment on neurovascular dysfunction in diabetic rats
46. Widespread vascular barrier dysfunction induced by diabetes and by LY333531 a β-selective inhibitor of protein kinase C
47. 2+-sensitive isoforms in the failing human heart
48. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
49. Therapeutic potentiation by a protein kinase Cβ inhibitor (LY333531) along with radiation or chemotherapy
50. Salt form selection and characterization of LY333531 mesylate monohydrate
51. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKCbeta inhibitor, in healthy subjects
52. 14C-LY333531 in healthy male volunteers
53. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC-β inhibitor in healthy elderly subjects
54. Amelioration of abnormal retinal hemodynamics by a protein kinase Cβ selective inhibitor LY333531 in patients with diabetes: Results of a phase I safety and pharmacodynamic clinical trial
55. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class